Beyond Air (XAIR) Q3 2026 earnings review
Breakout Quarter: Revenue Jumps, Margins Flip Positive
Beyond Air delivered its strongest quarter to date, breaking a two-quarter revenue plateau with 21% sequential growth to $2.2M (+105% YoY). Critically, the company reported positive Gross Profit ($0.3M) for the first time in recent history, proving the unit economics of the LungFit model work at scale. While the Net Loss remains substantial (-$7.3M), aggressive cost-cutting reduced operating expenses by 36% YoY. With a strategic divestiture of NeuroNOS clearing the deck and a pro forma cash runway into 2027, execution risk is decreasing, though the high end of FY26 revenue guidance appears mathematically improbable.
🐂 Bull Case
Gross margin flipped from -20% a year ago to +13.6% this quarter. As volume scales, the leverage on the LungFit tankless model is finally showing up in the numbers.
Divesting 85% of the NeuroNOS subsidiary to XTL Biopharmaceuticals removes a distraction and cash drain while retaining upside (19.9% equity + milestones). Combined with recent financing, cash runway now extends into calendar 2027.
🐻 Bear Case
To hit the top end of the maintained $8-10M guidance, XAIR needs ~$4.2M in Q4—nearly doubling Q3 revenue sequentially. This implies a significant miss at the top end is likely.
Despite improvements, the company burned ~$4.3M in cash to generate $2.2M in revenue. The path to self-funding remains long and dependent on the Gen II launch.
⚖️ Verdict: 🟢
Constructive. The transition to positive gross margins and the breakout in revenue growth are pivotal. The balance sheet is repaired for the next 12-18 months. If they can execute the Gen II launch in late 2026, the thesis holds.
Key Themes
NeuroNOS Divestiture / XTL Deal
A major strategic cleanup. Beyond Air signed a binding LOI for XTL Biopharmaceuticals to acquire 85% of its NeuroNOS subsidiary. XAIR receives ~$1M cash, 19.99% of XTL equity, and up to $31.5M in milestones. This removes R&D overhead for a non-core asset while keeping a lottery ticket for future success.
Commercial Traction & VA Entry
The company secured its first sale to a VA Medical Center. Breaking into the VA system (the largest US healthcare network) validates the technology and simplifies future government sales. International distribution also expanded to 40 countries, providing a secondary growth layer.
Gen II Launch Dependency
Management reiterated the second-generation LungFit PH system (smaller, transport-ready) is expected to receive FDA clearance before the end of calendar 2026. This product is critical for mass adoption. Any regulatory slip would be punishing given the current valuation relies on this expansion.
Implied Q4 Ramp is Unrealistic
Maintained guidance of $8-10M implies Q4 revenue between $2.2M (flat QoQ) and $4.2M (+90% QoQ). The lack of a guidance trim suggests either a massive pending order or a management team unwilling to reset expectations until the last moment.
Cost Discipline Execution
Total operating expenses dropped to $6.9M from $10.7M YoY (-36%). SG&A specifically fell 42%. This demonstrates management is effectively right-sizing the organization to preserve cash while still growing the top line.
Other KPIs
Reversing. A massive swing from -20% in the prior year period. Positive gross profit is the first essential step toward viability for a medical device company.
Stable. Includes Dec 31 balance of $17.8M plus $4.5M net proceeds from Jan 2026 financing. Management claims runway into calendar 2027.
Improving. Burn excludes financing inflows. While still double revenue, it is significantly lower than the >$7M burn rates seen in FY25.
Guidance
Maintained. YTD revenue is $5.78M. To hit the bottom end ($8M), Q4 must be ~$2.22M, which is flat sequentially and highly achievable. To hit the top end ($10M), Q4 needs to be ~$4.2M, which is unlikely. The effective guidance is the low end.
Extended. Previously 'well into calendar 2026'. The financing in January plus the NeuroNOS divestiture has bought the company an additional 2-3 quarters of breathing room.
Key Questions
Guidance Reconciliation
To reach the upper end of the $10M guidance, Q4 revenue needs to nearly double sequentially to ~$4.2M. Is there a specific large order or tender committed for Q4 that supports this, or should investors anchor to the low end?
VA Sales Cycle
With the first VA sale completed, what is the typical lag time for broader adoption across the VA network? Is this a centralized purchasing decision or hospital-by-hospital?
Gross Margin Trajectory
Now that Gross Margin is positive (13.7%), what is the target steady-state margin for Gen I devices, and how does the introduction of Gen II in late 2026 impact COGS initially?